QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic

Owens & Minor

Thermo Fisher Scientific

Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

Abbott Labs

Quest Diagnostics

Labcorp Holdings Inc

Our indicative theme of Covid-19 Testing Stocks- which includes the stocks of companies that produce or carry out tests for the highly infectious virus - is up by about 51% year-to-date, on an equally weighted basis, compared to the broader S&P 500 which is up around 15%. While the conversation.

Quidel, Abbott, Quest: Why Covid-19 Testing Stocks Are Still Worth A Look

Fulgent Genetics

Although vaccine makers are dominating headlines, these diagnostic companies will remain relevant in the fight against COVID-19.

2 Solid Coronavirus Testing Stocks to Buy Now

Ultra Clean

Top Ranked Growth Stocks to Buy for December 2nd

Quidel (QDEL) possesses solid growth attributes, which could help it handily outperform the market.

Quidel (QDEL) is an Incredible Growth Stock: 3 Reasons Why

TopBuild

Fair Isaac

After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.

5 Best Momentum Picks Using Driehaus Strategy

Is (QDEL) Outperforming Other Medical Stocks This Year?

Has Quidel (QDEL) Outpaced Other Medical Stocks This Year?

Digital Turbine

Aviat Networks

Calix

Cambium Networks Corp

eXp World Holdings Inc

Sunopta

Tupperware

Vista Outdoor

While the gains are broad based, we have highlighted 10 stocks - APPS, OMI, EXPI, TUP, STKL, CALX, VSTO, CMBM, QDEL and AVNW - that have been on the forefront of the rally this year.

10 Stocks That Deserve Thanks in Pandemic-Ravaged 2020

SAN DIEGO--(BUSINESS WIRE)-- #COVID19--Health care professionals to join a webinar focused on how to correctly diagnose and treat the look-alike conditions of Lyme disease, flu and COVID.

Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season

IDEXX Laboratories

Repligen

Veeva Systems

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why It Might Be Time To Pay Attention To These 4 Red-Hot Health Stocks

Logitech

Hologic (HOLX), Logitech (LOGI) and Quidel (QDEL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Buy These 3 Momentum Anomaly Stocks to Maximize Your Returns

Align Technology

Insulet

ResMed

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign

Quidel Corporation, the manufacturer of diagnostic healthcare products, is heavily involved in the testing response to the global pandemic. The stock has surged over 20% in the past month on earnings news and is up over 300% this year.

Quidel Corporation: COVID-19 Testing Play That Has Plenty Of Room To Run

Honeywell

Momenta Pharmaceuticals

Sony

Billionaire investor Mario Gabelli (Trades, Portfolio), leader of New York-based GAMCO Investors, disclosed his third-quarter portfolio earlier this week.

Mario Gabelli's Top 5 Trades of the 3rd Quarter

SAN DIEGO--(BUSINESS WIRE)-- #awardwinner--Quidel Corporation has been honored with three awards for creative excellence from the international MarCom Awards competition.

Quidel Corporation Triple Winner in International MarCom Awards Competition

Guardant Health Inc

These two diagnostics companies are trying to cash in on demand for coronavirus tests.

Better Coronavirus Stock: Quidel or Guardant Health?

Axon Enterprise

Archer-Daniels-Midland Company

Blink Charging

Twenty-First Century Fox

Johnson & Johnson

NextEra Energy

Sturm, Ruger & Company

Wheaton Precious Metals

While coronavirus numbers start to subside again, many investors are in a pandemic mentality, making these the stocks to buy this week. The post 9 Outbreak-Fueled Stocks to Buy This Week appeared first on InvestorPlace.

9 Outbreak-Fueled Stocks to Buy This Week

Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period. Covid-19 testing stocks could be.

Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will host its Quidel Investor Day 2020 event virtually on Thursday, November 12, 2020. Quidel's management presentation will begin at 8:00 a.m. Pacific Time, to be immediately followed by a question and answer session. During the presentation, the Company will discuss business and financial developm

Quidel to Host Virtual Investor Day on November 12, 2020

Zai Lab Ltd.

The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio earlier this week.

Vanguard Health Care Fund Adds 3 Positions to Portfolio

DexCom

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Moderna

Pfizer

If you're interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip. The post Which Biotech Stocks Are a Buy on Earnings?

Which Biotech Stocks Are a Buy on Earnings?

Quidel's (QDEL) CEO Doug Bryant on Q3 2020 Results - Earnings Call Transcript

Quidel (QDEL) delivered earnings and revenue surprises of 26.20% and -0.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Q3 Earnings Beat Estimates

Shares of Quidel (NASDAQ:QDEL) fell 1.5% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 725.71% over the past year to $5.78, which beat the estimate of $4.75.

Recap: Quidel Q3 Earnings

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights Total revenue increased 276% to $476.1 million, from $126.5 million in the third quarter of 2019. Total sales of COVID-19 products were $375.7 million. Reported GAAP EPS of $5.33 per diluted share in the third

Quidel Reports Third Quarter 2020 Financial Results

News for QuidelOrtho Corp Stock (QDEL)